Assessing Toxicity Risk in Senior Chemotherapy Patients (AT RISC) a pilot prospective audit
|
|
- Amie Logan
- 5 years ago
- Views:
Transcription
1 Assessing Toxicity Risk in Senior Chemotherapy Patients (AT RISC) a pilot prospective audit Dr Laird Cameron MBChB BSc, Dr Annie Wong MBChB, Dr C Barrow MBChB, Dr K Clarke MBChB, Dr B Luey MBChB, Dr A Fenton MBBS, Dr K Gregory MD, Dr Anne O Donnell MD Wellington Blood and Cancer Centre, Wellington Hospital, CCDHB NZSO July 2013
2 Introduction NZ population is aging 1 and cancer incidence rises with age 2 Elderly patients can derive the same survival benefits from chemotherapy 3 Chronological age does not equal physiological age 4 Elderly patients are at increased risk of chemotherapy toxicity 5 1.Statistics New Zealand Smith et JCO Sargent et al NEJM Soubeyran JCO Muss et al JCO 2007
3 Introduction National Cancer Institute: Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life threatening Grade 5: Fatal
4 Introduction Performance status can be used to predict toxicity in chemotherapy patients 6 6. Schag et al JCO 1984
5 Introduction Chemotherapy toxicity predictive scores in CRASH Score 7 the elderly. 518 pts predict risk of G4H/G3-4NH toxicity Bloods: lymphocyte, AST, LDH, CrCl, Alb IADL, DBP, Chemotox, MMSE, ECOG, Nutritional assessment, self rated health assessment Difficult to implement Hurria score pts predict risk of G3-5 toxicity during new line of chemo Needs validation before use in NZ setting 7. Extermann et al Cancer Hurria et al JCO 2011
6 Introduction Hurria: Factors validated for predictive score Age (> 72) Cancer type (GI/GU 2, other 0) Chemotherapy Dosing (standard) Polychemotherapy Physiology Haemoglobin (< 110g/L M, < 100g/L F) Creatinine clearance (<34ml/min) Function Self reported hearing impairment (fair or worse) Falls in last 6 months (1 or more) Taking medications (need assistance) Walking 1 block (limited) Decreased social activity due to physical/emotional health (limited, at least sometimes)
7 Introduction Hurria score vs KPS
8 Method 7 months (Oct 2012 May 2013) at Wellington Hospital Patients >65yr old starting new line of chemotherapy for any solid tumour. Clinicians completed audit tool Retrospective data collection for Grade 3-5 Toxicity Hospital admission or clinic visits To define the toxicity rates, patients were censored at the first G3-5 toxicity Toxicity defined by CTCAE v3.0 Clinicians estimated perceived risk of toxicity Feasibility questionnaire
9 Results Patient selection 65 audited 15 not yet completed chemotherapy 50 completed chemotherapy 46 included in data analysis 4 discontinued chemotherapy in cycle 1, clearly due to progressive disease
10 Results Patient characteristics Age mean (SD,range) ATRISC (n=46) 73 (5.7, 65 to 90) Hurria (n=500) 73 (6.2, 65 to 91) Sex (% Female) Ethnicity (%) NZ European 84 Maori 1 Pacific Island 5 Asian 1 Other 8 KPS (%) range % >70 White 85 Black 8 Asian 5 Other % >70.
11 Results Tumour and treatment characteristics ATRISC (n=46) Hurria (n=500) Cancer type (%) Breast Lung GI GYN GU 3 10 Other 12 6 Cancer Stage (%) I 0 5 II 5 12 III IV st Line Chemotherapy (%) Standard dose chemotherapy (%) Combination chemotherapy (%) Primary GCSF prophylaxis (%) 6 18
12 Results Toxicity ATRISC (n=46) Hurria (n=500) Overall Grade 3 to 5 Toxicity n (%) 32 (70) 265 (53) Type n (%) Haematologic Non-Haematologic Fatigue Renal/electrolyte Non Neutropenic Infection VTE Gastro Neuropathy Nausea 14 (30) 23 (50) 5 (11) 2 (4) 5 (11) 1 (2) 6 (13) 1(2) 1 (2) 131 (26) 217 (43) 81 (16) 80 (16) 48 (10) 22 (4) 22 (4) 13 (3) 12 (2) Grade 5 n (%) Nil 10 (2)
13 Results Patients (%) Toxicity clustered by Hurria score Grade 3 to 5 Toxicity ATRISC LOW MED HIGH Total Risk Score (Median 7.5) HIGH Hurria MED LOW (Median 7.0)
14 Results Patients (%) Toxicity clustered by KPS Grade 3-5 Toxicity (%) ATRISC <70 Physician-Rated KPS (%) Hurria
15 Patient Number Patient number Results Toxicity clustered by clinician estimate Registrar Estimated Toxicity n= Toxicity Estimation (%) Toxicity No Toxicity Consultant Estimated Toxicity n= Toxicity Estimation (%)
16 Results Feasibility 11 Clinicians surveyed. Question Easy to use? How much time did it add to the consult? Complete all parts easily? Main barrier? Response 100% Yes 75% <5min. 75% Yes Remembering to include it in the consult.
17 Conclusion Feasibility Pilot study: easily implemented. Clinicians cannot reliably predict toxicity in this elderly population. Our numbers are small and we have not attempted to draw statistically significant conclusions No suggestion of correlation between Hurria risk score and toxicity. This may be related to differences in our tumour types. Before widespread clinical use, an adequately powered study needs to be conducted in our local population
18 Thank you for your attention
19
20
21
22
23 Elderly patients under-represented in cancer-related treatment trials
Geriatric Assessment to Improve Outcomes for Older Adults with Cancer
Geriatric Assessment to Improve Outcomes for Older Adults with Cancer Allison Magnuson, DO Assistant Professor of Medicine University of Rochester Medical Center Objectives Appreciate the demographics
More informationLung Cancer in Older Adults.. Appropriate treatment?
Lung Cancer in Older Adults.. Appropriate treatment? Faculty Disclosure X No, nothing to disclose Yes, please specify: Dr Christopher Steer Border Medical Oncology Albury-Wodonga Inaugural Chair Geriatric
More informationCommunicating Treatment Options to Older Patients: Challenges and Opportunities
Communicating Treatment Options to Older Patients: Challenges and Opportunities Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope National Medical Center Duarte, California, USA
More informationBasics in Geriatric Oncology. Ravindran Kanesvaran Consultant Medical Oncologist and Course Director National Cancer Centre Singapore
Basics in Geriatric Oncology Ravindran Kanesvaran Consultant Medical Oncologist and Course Director National Cancer Centre Singapore How did it start? Ongoing geriatric oncology service at NCCS ( the only
More informationGeriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationDISCLOSURES LEARNING OBJECTIVES DEFINITIONS
GERIATRIC ONCOLOGY: AN OVERVIEW OF CONSIDERATIONS IN OLDER ADULTS RECEIVING CANCER TREATMENT Mark Pasetka Clinical Pharmacy Coordinator Odette Cancer Centre Sunnybrook Health Sciences Centre 27 April 2019
More informationIntegrating Geriatrics into Oncology Care
Integrating Geriatrics into Oncology Care William Dale, MD, PhD Chief, Geriatrics & Palliative Medicine Director, Specialized Oncology Care & Research in the Elderly (SOCARE) Clinic University of Chicago
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationImproving the Survivorship of Older Adults with Cancer Using Geriatric Assessment
Improving the Survivorship of Older Adults with Cancer Using Geriatric Assessment Deborah Bacon, RN,BSN Geriatric Oncology Clinical Nurse Coordinator James P Wilmot Cancer Institute Outline Geriatric assessment
More informationPaul Calabresi Award. From suboptimal to optimal treatment in older patients with cancer. Pierre Soubeyran, MD, PhD
Paul Calabresi Award From suboptimal to optimal treatment in older patients with cancer Pierre Soubeyran, MD, PhD Institut Bergonié, Université Bordeaux Segalen Health status-adapted cancer care Balance
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationHazardous drinking in 2011/12: Findings from the New Zealand Health Survey
Hazardous drinking in 11/12: Findings from the New Zealand Health Survey This report presents key findings about alcohol use and hazardous drinking among adults aged 15 years and over, which come from
More informationBreast cancer in elderly
Breast cancer in elderly IBDC Feb 6, 2013 Etienne Brain, MD, PhD Medical Oncology HÔPITAL RENÉ HUGUENIN Au 1 er janvier 2010, le Centre René Huguenin devient l Hôpital René Huguenin, un établissement de
More informationBladder'Cancer'in'the' Elderly
4/20/15 Bladder'Cancer'in'the' Elderly Hamidreza)Abdi,)MD,FEBU Clinical) Fellow Department) of)urologic)sciences UBC April&2015 Objectives! 1.1Review1changing1demographics1of1patients1with1 bladder1cancer1as1the1general1population1
More informationAC-DOCE Regimen. AC-DOCE+TRAS Regimen AC-DOCE AC-DOCE+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed :
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationBlakely T, Tobias M et al. Tracking disparity: Trends in ethnic and socioeconomic inequalities in mortality, Wellington: Ministry of
Ethnic disparities in colon cancer survival in New Zealand Dr Diana Sarfati University of Otago Wellington Māori Cancer Conference; Aug 2009 Acknowledgements Sarah Hill Project team Bridget Robson, Donna
More informationSummary of the BreastScreen Aotearoa Mortality Evaluation
Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011 Released 2015 nsu.govt.nz Citation: Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011. Wellington:
More informationBreast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer Indication: Alternative palliative treatment for advanced breast cancer in patients where docetaxel monotherapy or docetaxel/capecitabine
More informationAlister Jones Patient Blood Management Practitioner NHS Blood and Transplant
Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant All medical RCC transfusions (but only 1 in 3 haematology or oncology cases) in 3 x one week periods Medical specialties include:
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationMeet the Professor Dosing and toxicity management
Meet the Professor Dosing and toxicity management Lodovico Balducci & Catherine Terret Mrs. Marie O. 78 years Right breast tumor : 50 mm, upper outer quadrant, Node: 0 Biopsy (9 Dec 2009) Invasive ductal
More information2017 Repeat Audit of Red cell and Platelet Transfusion in Adult Haematology Patients
07 Repeat Audit of Red cell and Platelet Transfusion in Adult Haematology Patients Haematology Audit July 07 The audit was conducted on adults undergoing surgery and who received a transfusion during a
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More informationProblems related to the management of malignant hemopathies in older patients
Problems related to the management of malignant hemopathies in older patients Dr Marie Maerevoet Gent, 25 January 2013 BHS satellite symposium on Elderly Malignant Hemopathies in older patients - 33% of
More informationComorbidities and cancer Applications to non small cell lung cancer
Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014
More informationDietary supplement use in cancer patients: is there a link to psychosocial wellbeing?
Dietary supplement use in cancer patients: is there a link to psychosocial wellbeing? Kathryn Taylor Clinical Psychologist St George s Cancer Care Centre St George s Cancer Care Centre Dietary supplements
More informationChapter 10. Cancer. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter Cancer 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Incidence of Cancer on Renal Replacement Therapy Figures.1-.6 and table.1 show the cumulative incidence of non-skin cancer in patients
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1* to 5 Prednisolone 40mg/m 2 Oral Once Daily For 5 days 1 Paracetamol 1gram Oral Once Only Chlorphenamine 10mg IV bolus Ondansetron 8mg IV
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationFeasibility of an Electronic Geriatric Assessment (ega) for Older Adults with Cancer
Feasibility of an Electronic Geriatric Assessment (ega) for Older Adults with Cancer Study Group: Emily Guerard MD, Ryan Nipp MD, Grant Williams MD, Armin Shahrokni MD, Jeff Sloan PhD, Travis Dockter MS,
More informationSymptom Control During Chemotherapy (SCDC) MN Community Measurement
Symptom Control During Chemotherapy (SCDC) MN Community Measurement MN Community Measurement Nonprofit health care quality improvement and reporting organization Specialize in developing, collecting, analyzing
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationTrial Designs for Older Oncology Patients. Karla Ballman Division Chief and Professor of Biostatistics and Epidemiology 14 September 2018
Trial Designs for Older Oncology Patients Karla Ballman Division Chief and Professor of Biostatistics and Epidemiology 14 September 2018 1 Overview Problem Endpoints Designs 2 Problem Under representation
More informationBortezomib, Thalidomide & Dexamethasone
DRUG ADMINISTRATION SCHEDULE Cumbria, Northumberland, Tyne & Wear Area Team Day Drug Dose Route Diluent Rate 1, 4, 8, & 11 2 Bortezomib 1.3mg/m IV bolus/ SC injection* None Fast bolus: 3 to 5 seconds 1
More informationEarly Integration of Palliative Care
Early Integration of Palliative Care Dr. Camilla Zimmermann Head, Palliative Care Program University Health Network Toronto November 1, 2014 www.fpon.ca Early Integration of Palliative Care: Evidence and
More informationPalliative Care The Benefits of Early Intervention
The Royal Marsden Palliative Care The Benefits of Early Intervention Dr Anna-Marie Stevens, Nurse Consultant Symptom Control and Palliative Care Team, The Royal Marsden NHS Foundation Trust, London, UK
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationDiagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems
Diagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems HCSRN 2019 Conference April 10, 2019 Kaiser Permanente Research Peripheral neuropathy is a common side effect of neurotoxic
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationManagement of Anaemia reduces Red cell Transfusion in NI. Dr Susan Atkinson NI Transfusion Committee
Management of Anaemia reduces Red cell Transfusion in NI Dr Susan Atkinson NI Transfusion Committee BBTS September 2014 Patient and Client Council Department of Health Chief Medical Officer Expert Professionals
More informationVinorelbine (Navelbine ) plus Capecitabine (Xeloda ) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Vinorelbine 60 to 80 mg/m 2 Oral N/A Stat Dose Days 1 to 14 Capecitabine 1000 mg/m 2 twice a day* Vinorelbine Capecitabine protocolcrp11b0024
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationThe Role that Geriatricians Can Play in the Care of Older Patients with Cancer Across the Care Continuum
The Role that Geriatricians Can Play in the Care of Older Patients with Cancer Across the Care Continuum Holly M. Holmes, MD, MS Associate Professor and Division Director Geriatric and Palliative Medicine
More informationBreast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer
Breast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer Indication: Regimen details: Administration: Frequency: Pre-medication: Anti- emetics: Supportive medication: Extravasation:
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationNPAC(W)+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationRehabilitation of the Older Cancer Patient. Lodovico Balducci, M.D. Moffitt Cancer Center Tampa, Florida
Rehabilitation of the Older Cancer Patient Lodovico Balducci, M.D. Moffitt Cancer Center Tampa, Florida Rehabilitation of the older cancer patient Is cancer treatment effective in older individuals? Chronologic
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationCAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1) Capecitabine (Xeloda) monotherapy is indicated for the treatment of locally advanced
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationOF LIFE AMONG OLDER ADULTS WITH HEMATOLOGIC MALIGNANCIES
GERIATRIC ASSESSMENT AND QUALITY OF LIFE AMONG OLDER ADULTS WITH HEMATOLOGIC MALIGNANCIES Daneng Li, MD Assistant Clinical Professor Medical Oncology & Therapeutics Research Erin Kopp M.S.N, A.C.N.P-B.C.,
More informationWhat were the key findings from the routinely-collected data?
What were the key findings from the routinely-collected data? Dr Jason Gurney MoH National Health Board Cancer Registry (n=14,096) Hospitalisation and other Databases Mortality Database Notes Review (Upper
More informationChapter 10. Cancer. ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong.
Chapter Cancer ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong Contents: Cancer -1 Incidence of Cancer on Renal Replacement Therapy -2 Kidney Cancer
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationCo-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake
Co-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Questionnaire to Site- Specific
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationGLI EFFETTI COLLATERALI DELLE TERAPIE IN ONCOLOGIA GERIATRICA. Fausto Meriggi U.O. Oncologia Medica Fondazione Poliambulanza, Brescia
GLI EFFETTI COLLATERALI DELLE TERAPIE IN ONCOLOGIA GERIATRICA Fausto Meriggi U.O. Oncologia Medica Fondazione Poliambulanza, Brescia SIGG Torino 28-11-2013 Il 39% (quasi 900.000 soggetti) ha un età
More informationBlood Cancers in the Community
Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James
More informationGERIATRIC ONCOLOGY. An Introduction. Dr Lissandra Dal Lago, MD, PhD Dr Noam Pondé, MD Institut Jules Bordet, Brussels, Belgium
An Introduction Dr Lissandra Dal Lago, MD, PhD Dr Noam Pondé, MD Institut Jules Bordet, Brussels, Belgium PLAN OF MODULE Demographics of cancer and aging Chronological age vs. functional age The aging
More informationFuture Direction for Cancer Registries
Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk In Ye Olde Days. 8 regional cancer registries Variation
More informationCPAG Summary Report for Clinical Panel 1608 Bendamustine for relapsed multiple myeloma
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel 1608 Bendamustine for relapsed multiple myeloma The Benefits of the Proposition (Grade of Evidence to be left blank) No Outcome measures
More informationThe SOCARE Model of Cancer Care for Older Adults: Building Infrastructure and Policies for Truly Personalized Cancer Care for an Aging Society
The SOCARE Model of Cancer Care for Older Adults: Building Infrastructure and Policies for Truly Personalized Cancer Care for an Aging Society William Dale, MD, PhD Michael M Davis Lecture Series University
More informationA Special Project of the Auckland Breast Cancer Study Group. - prepared by Wendy Dykes (Ak. Breast Cancer Register Data Manager)
A Special Project of the Auckland Breast Cancer Study Group - prepared by Wendy Dykes (Ak. Breast Cancer Register Data Manager) Breast Cancer is a serious public health issue in New Zealand, Auckland alone
More informationCARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER
CARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER MARTINE EXTERMANN, MD, PHD MOFFITT CANCER CENTER, UNIVERSITY OF SOUTH FLORIDA TAMPA, FL, USA JEOPARDY CATEGORIES Age as a risk factor
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationNCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment HER2 positive early breast cancer C50 00258a Hospital
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationIntegrating Palliative and Oncology Care in Patients with Advanced Cancer
Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More informationTrends and disparities in cancer in Aotearoa/ NZ
Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both
More informationBortezomib and Dexamethasone Therapy INDICATIONS FOR USE:
Bortezomib and Dexamethasone Therapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy ICD10 C90 Protocol Code 00270a
More informationEffects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor. City of Hope Medical Center
Effects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor City of Hope Medical Center Duarte, California. Pre-Chemotherapy e e apycognitive Functioning
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationOptimising asthma management in high risk patients
C L I N I C A L AU D I T Optimising asthma management in high risk patients Valid to June 2022 bpac nz better medicine Audit focus This audit helps primary care health professionals identify patients with
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationCapecitabine plus Docetaxel in Advanced Breast Cancer
Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*
More informationNCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationWaikato Breast Cancer Register March 2010
Waikato Breast Cancer Register March 2010 Demographics - Population: Total New Waikato Breast Cancers Diagnosed 2005 2008 1072 Total Patients Eligible for WBCR 1008 Total Records Entered into WBCR (95%
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationAppendix Two. Epidemiology of HER2-positive breast cancer in New Zealand including regional and ethnic disparties
Appendix Two. Epidemiology of HER2-positive breast cancer in New Zealand including regional and ethnic disparties Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationCancer associated thrombosis palliative care and the end of life. Tracy Anderson May 2017
Cancer associated thrombosis palliative care and the end of life Tracy Anderson May 2017 Treatment at the end of life Can be challenging to know what treatments are appropriate Benefit vs burden Patients
More information